

# Malignant Mesothelioma - Pipeline Review, H1 2020

<https://marketpublishers.com/r/MC99AA041E5EN.html>

Date: March 2020

Pages: 1024

Price: US\$ 2,000.00 (Single User License)

ID: MC99AA041E5EN

## Abstracts

Malignant Mesothelioma - Pipeline Review, H1 2020

### SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2020, provides an overview of the Malignant Mesothelioma (Oncology) pipeline landscape.

Malignant pleural mesothelioma is a rare cancer often diagnosed in people who have been exposed to high levels of asbestos. The malignancy affects the pleura, a thin membrane of lubricating cells that lines the lungs and chest wall. Peritoneal mesothelioma originates in the abdomen and as a result, symptoms often include abdominal pain, weight loss, nausea, and vomiting. Other symptoms include anemia, bowel obstructions, chest pain and hemoptysis.

### REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Malignant Mesothelioma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Malignant Mesothelioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Malignant Mesothelioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Malignant Mesothelioma and features dormant and discontinued projects. The guide covers therapeutics under Development by

Companies/Universities/Institutes, the molecules developed by Companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 9, 43, 37, 25, 2 and 2 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 6, 6 and 8 molecules, respectively.

Malignant Mesothelioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Malignant Mesothelioma (Oncology).

The pipeline guide reviews pipeline therapeutics for Malignant Mesothelioma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Malignant Mesothelioma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Malignant Mesothelioma (Oncology) therapeutics

based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Malignant Mesothelioma (Oncology)

## **REASONS TO BUY**

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Malignant Mesothelioma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Malignant Mesothelioma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

## Contents

Introduction

Malignant Mesothelioma - Overview

Malignant Mesothelioma - Therapeutics Development

Malignant Mesothelioma - Therapeutics Assessment

Malignant Mesothelioma - Companies Involved in Therapeutics Development

Malignant Mesothelioma - Drug Profiles

Malignant Mesothelioma - Dormant Projects

Malignant Mesothelioma - Discontinued Products

Malignant Mesothelioma - Product Development Milestones

Appendix

## List Of Tables

### LIST OF TABLES

Number of Products under Development for Malignant Mesothelioma, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Products under Development by Companies, H1 2020  
Products under Development by Universities/Institutes, H1 2020  
Products under Development by Universities/Institutes, H1 2020 (Contd..1), H1 2020  
Number of Products by Stage and Target, H1 2020  
Number of Products by Stage and Mechanism of Action, H1 2020  
Number of Products by Stage and Route of Administration, H1 2020  
Number of Products by Stage and Molecule Type, H1 2020  
Malignant Mesothelioma - Pipeline by AbbVie Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Agios Pharmaceuticals Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Akeso Biopharma Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Aldeyra Therapeutics Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Almac Discovery Ltd, H1 2020  
Malignant Mesothelioma - Pipeline by Amphera BV, H1 2020  
Malignant Mesothelioma - Pipeline by AnGes Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Apollomics Inc, H1 2020  
Malignant Mesothelioma - Pipeline by Applied Research using OMIC Sciences SL, H1 2020  
Malignant Mesothelioma - Dormant Projects, H1 2020  
Malignant Mesothelioma - Discontinued Products, H1 2020  
Malignant Mesothelioma - Discontinued Products, H1 2020 (Contd..1), H1 2020

## List Of Figures

### LIST OF FIGURES

Number of Products under Development for Malignant Mesothelioma, H1 2020  
Number of Products under Development by Companies, H1 2020  
Number of Products under Development by Universities/Institutes, H1 2020  
Number of Products by Top 10 Targets, H1 2020  
Number of Products by Stage and Top 10 Targets, H1 2020  
Number of Products by Top 10 Mechanism of Actions, H1 2020  
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020  
Number of Products by Top 10 Routes of Administration, H1 2020  
Number of Products by Stage and Top 10 Routes of Administration, H1 2020  
Number of Products by Top 10 Molecule Types, H1 2020  
Number of Products by Stage and Top 10 Molecule Types, H1 2020

### COMPANIES MENTIONED

AbbVie Inc  
Agiros Pharmaceuticals Inc  
Akeso Biopharma Inc  
Aldeyra Therapeutics Inc  
Almac Discovery Ltd  
Amphera BV  
AnGes Inc  
Apollomics Inc  
Applied Research using OMIC Sciences SL  
Argenx SE  
Ascentage Pharma Group International  
AstraZeneca Plc  
Atara Biotherapeutics Inc  
Aurigene Discovery Technologies Ltd  
Bayer AG  
BerGenBio ASA  
Biocad  
Biogen Inc  
Bionomics Ltd  
Boehringer Ingelheim International GmbH  
Boston Biomedical Inc

Bristol-Myers Squibb Co  
Calithera Biosciences Inc  
CanBas Co Ltd  
Canget BioTekpharma LLC  
Checkpoint Therapeutics Inc  
Chiome Bioscience Inc  
Clovis Oncology Inc  
CStone Pharmaceuticals Co Ltd  
Deciphera Pharmaceuticals Inc  
Delta-Fly Pharma Inc  
Eisai Co Ltd  
Eli Lilly and Co  
EnGeneIC Ltd  
Epigene Therapeutics Inc  
Epizyme Inc  
F. Hoffmann-La Roche Ltd  
FKD Therapies Oy  
Flag Therapeutics Inc  
Genelux Corp  
GlaxoSmithKline Plc  
H2Biologics Inc  
Harpoon Therapeutics Inc  
Hebei Senlang Biotechnology Inc Ltd  
Horizon Therapeutics PLC  
Hutchison MediPharma Ltd  
IDAC Theranostics Inc  
Incyte Corp  
Infinity Pharmaceuticals Inc  
Inhibrx Inc  
Inventiva  
Invion Ltd  
Juno Therapeutics Inc  
Karyopharm Therapeutics Inc  
Kiromic BioPharma Inc  
L.E.A.F. Pharmaceuticals LLC  
Laboratoires Pierre Fabre SA  
Leucid Bio Ltd  
Lipac Oncology LLC  
LipoSeuticals Inc

MacroGenics Inc  
Marino Biotechnology Co Ltd  
MELEMA Pharma GmbH  
Merck & Co Inc  
Merck KGaA  
Millennium Pharmaceuticals Inc  
Minneamrita Therapeutics LLC  
Molecular Partners AG  
MolMed SpA  
MTG Biotherapeutics Inc  
NeoTX Therapeutics Ltd  
Novartis AG  
Oasmia Pharmaceutical AB  
Oncology Venture U.S. Inc  
Ono Pharmaceutical Co Ltd  
OSE Immunotherapeutics  
Pharma Mar SA  
PlumeStars Srl  
Polaris Pharmaceuticals Inc  
Seattle Genetics Inc  
SELLAS Life Sciences Group Inc  
Shanghai GeneChem Co Ltd  
Shanghai Keqi Pharmaceutical Technology Co Ltd  
Sotio AS  
Targovax ASA  
TCR2 Therapeutics Inc  
TRACON Pharmaceuticals Inc  
TREAT U SA  
Ube Industries Ltd  
Ultimovacs AS  
VasGene Therapeutics Inc  
Venus Remedies Ltd  
Verastem Inc  
Xencor Inc  
Y's Therapeutics Co Ltd  
Zhengda Tianqing Kangfang Shanghai Biomedical Technology Co Ltd



## I would like to order

Product name: Malignant Mesothelioma - Pipeline Review, H1 2020

Product link: <https://marketpublishers.com/r/MC99AA041E5EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/MC99AA041E5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970